Dimension Therapeutics, a developer of gene therapies for people living with rare diseases associated with the liver, has set an estimated price range of $14 to $16 for its IPO. If shares price at the midpoint of that range, the company would raise $82.5 million. Planning to list on the NASDAQ under the symbol DMTX, Dimension intends to use a significant portion of the proceeds to advance various drug candidates through Phase I/II clinical trials. It has raised roughly $90 million in VC funding to date, which includes a $65 million round in April that generated a valuation of $219 million. Investors include New Leaf Venture Partners and OrbiMed Advisors.